Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05305105 · ClinicalTrials.gov registry record · Phase 1
Effects of Psilocybin in Post-Treatment Lyme Disease
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05305105: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT05305105 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05305105, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2025-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05305105
The ClinicalTrials.gov registry entry for NCT05305105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT05305105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05305105 about?
NCT05305105 is a clinical study titled "Effects of Psilocybin in Post-Treatment Lyme Disease". This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).
What is the current status of trial NCT05305105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-07-01. Estimated completion is 2025-04-07.
What interventions are being tested in trial NCT05305105?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05305105?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.